Table 1.
Patient Characteristics | Total (n = 252) |
CYP3A5*1/*1 (n = 13) |
CYP3A5*1/*3 (n = 64) |
CYP3A5*3/*3 (n = 175) |
p-Value |
---|---|---|---|---|---|
Age | 52 (19–76) | 55 (27–68) | 50 (22–69) | 54 (19–76) | 0.09 |
Sex | |||||
Male | 145 (57.5%) | 7 (53.8%) | 32 (50%) | 106 (60.6%) | 0.39 |
Female | 107 (42.5%) | 6 (46.2%) | 32 (50%) | 69 (39.4%) | 0.39 |
Primary diagnosis | |||||
Aplastic Anemia | 5 (2%) | 1 (7.7%) | 1 (1.6%) | 3 (1.7%) | 0.32 |
Acute Leukemia | 139 (55.2%) | 7 (53.8%) | 31 (48.4%) | 101 (57.7%) | 0.44 |
Chronic Leukemia | 16 (6.3%) | 0 (0%) | 7 (10.9%) | 9 (5.1%) | 0.17 |
Lymphoma | 33 (13.1%) | 2(15.4%) | 10 (15.6%) | 21 (12%) | 0.74 |
MDS/MPS | 56 (22.2%) | 2 (15.4%) | 14 (21.9%) | 40 (22.9%) | 0.82 |
Myeloma | 3 (1.2%) | 0 (0) | 1 (1.6%) | 2 (1.1%) | 0.89 |
Donor | |||||
MUD | 165 (65.4%) | 8 (61.5%) | 23 (35.9%) | 56 (32%) | 0.09 |
MRD | 87 (34.6%) | 5 (38.5%) | 41 (64.1%) | 119 (68%) | 0.09 |
Stem cell source | |||||
PBSC | 237 (94%) | 11 (84.6%) | 61 (95.3%) | 165 (94.3%) | 0.32 |
BM | 14 (5.6%) | 1 (15.4%) | 3 (4.7%) | 10 (5.7%) | 0.90 |
Cord Blood | 1 (0.4%) | 1 (100%) | 0 (0%) | 0 (0%) | - |
Conditioning regimen | |||||
MAC | 131 (52%) | 4 (30.8%) | 38 (59.4%) | 89 (50.9%) | 0.15 |
RIC | 121 (48%) | 9 (69.2%) | 26 (40.6%) | 86 (49.1%) | 0.15 |
Race | |||||
White | 211 (83.7%) | 4 (1.9%) | 39 (18.5%) | 168 (79.6%) | <0.001 |
Black | 30 (11.9%) | 7 (53.8%) | 19 (29.7%) | 4 (2.3%) | <0.001 |
Other | 11 (4.4%) | 2 (18.2%) | 6 (54.5%) | 3 (27.3%) | 0.01 |
Drug-drug Interactions | |||||
No interaction | 19 (7.5%) | 3 (23.1%) | 4 (6.3%) | 12 (6.9%) | 0.09 |
Minimal risk interaction | 41 (16.3%) | 1 (7.7%) | 11 (17.2%) | 29 (16.6%) | 0.69 |
Moderate risk interaction | 183 (72.6%) | 9 (69.2) | 46 (71.9%) | 128 (73.1%) | 0.94 |
Severe risk interaction | 9 (3.6%) | 0 (0%) | 3 (4.7%) | 6 (3.4%) | 0.70 |
Median IBW, kg (range) | 85.1 (42.8–166.6) |
80.8 (60.2–109.2) |
86.6 (52.7–144.1) |
85.4 (42.8–166.6) |
0.15 |
Median tacrolimus starting daily dose, mg/dose (range) | 4.0 (1.0–8.0) | 4.0 (1.0–6.0) | 4.0 (2.0–8.0) | 5.0 (1.5–7.0) | 0.55 |
Median tacrolimus trough concentration, ng/mL (range) | 5.05 (0.6–27.1) | 2.8 (0.6–11.2) | 3.0 (0.8–14.4) | 6.2 (1.3–27.1) | <0.001 |
Median time to tacrolimus goal trough, days (range) | 6 (3–31) | 11 (3–31) | 8 (4–25) | 5 (3–16) | <0.001 |
Liver function tests at admission | |||||
AST (U/L) | 33.0 (5–206) | 33.0 (12–128) | 25.5 (10–127) | 26.0 (5–206) | 0.46 |
ALT (U/L) | 51 (12–209) | 42 (20–103) | 34.5 (14–177) | 39 (11–209) | 0.40 |
Tbili (mg/dL) | 0.58 (0.1–2.5) | 0.5 (0.1–1.4) | 0.6 (0.2–2.5) | 0.5 (0.1–2.1) | 0.73 |
SCr (mg/dL) at admission | 0.79 (0.34–1.58) | 0.80 (0.4–2.0) | 0.80 (0.3–1.8) | 0.70 (0.3–1.6) | 0.57 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BM, bone marrow; IDW, ideal body weight; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPS, mucopolysaccharidosis; MRD, match related donor; MUD, match unrelated donor; PBSC, peripheral blood stem cell; RIC, reduced-intensity conditioning; SCr, serum creatinine; Tbili, total bilirubin.